Bradley J. Monk, MD, Creighton University School of Medicine

home / authors / bradley-j-monk-md-creighton-university

Articles

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

July 1st 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Systemic Management of Ovarian Cancer: Closing Thoughts

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Ovarian Cancer: What is the Role of HRD Testing?

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Practical Applications of PRIMA in Ovarian Cancer Management

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

GOG-0218: Frontline Bevacizumab in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine;Thomas J. Herzog, MD;Thomas C. Krivak, MD;Sharyn N. Lewin, MD, Holy Name Medical Center;Kathleen N. Moore, MD, University of Oklahoma

May 27th 2020

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

March 1st 2019

The role of intraperitoneal chemotherapy in epithelial ovarian cancer has been a controversial subject for almost 3 decades; now, investigators are moving away from its use.

Dr. Monk on the FDA Approval of Pembrolizumab in Cervical Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

June 12th 2018

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Dr. Monk on the FORWARD I Trial in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

May 24th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FORWARD I trial in ovarian cancer.

Dr. Monk on Combination Therapies in Patients With Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

April 20th 2018

Bradley J. Monk, MD, professor and director, Division of Gynecologic Oncology, Creighton University School of Medicine, Arizona Oncology, discusses combination approaches in patients with ovarian cancer.

Dr. Monk on Choosing Between PARP Inhibitors in Ovarian Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

March 25th 2018

Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Monk on Bevacizumab in Recurrent Cervical Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

July 14th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

Dr. Monk on Trial Endpoints For Ovarian Cancer Agents

Bradley J. Monk, MD, Creighton University School of Medicine

February 17th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, on clinical trial endpoints and the approval of agents for ovarian cancer.

Dr. Monk on Bevacizumab in Cervical Cancer

Bradley J. Monk, MD, Creighton University School of Medicine

December 31st 2013

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.